Bivalirudin Trifluoroacetate is primarily used as an anticoagulant in medical settings. It is commonly administered during percutaneous coronary interventions (PCI), such as angioplasty, to prevent blood clotting. The compound is particularly beneficial for patients with heparin-induced thrombocytopenia (HIT), as it offers an alternative to heparin-based anticoagulants. Its rapid onset and short half-life allow for precise control over anticoagulation, reducing the risk of bleeding complications. Additionally, it is used in the management of acute coronary syndromes, providing effective anticoagulation during procedures. Its application ensures safer and more controlled outcomes in high-risk cardiovascular interventions.